| Assessment Status | Rapid Review Complete |
| HTA ID | 23063 |
| Drug | Cytisine |
| Brand | Citidaron® |
| Indication | Cytisine (Citidaron®) is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. |
| Assessment Process | |
| Rapid review commissioned | 09/10/2023 |
| Rapid review completed | 28/11/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that cytisine not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
